|
Synonyms: A-1230717 | ABT-122
Compound class:
Antibody
Comment: Remtolumab (ABT-122) is a dual-variable domain immunoglobulin (DVD-IgTM) that specifically neutralises both TNF alpha and interleukin-17A, which was investigated for clinical anti-rheumatic potential [1]. We note that ABT-122 is no longer included on the developer's (AbbVie) pipeline web page, suggesting that development has ceased. No affinity data is readily available in peer reviewed literature and we have failed to identify peptide sequences for both the IL-17A and TNFα binding domains of the antibody in any single patent document that would allow definitive identification of ABT-122, despite AbbVie holding several patents describing IL-17A/TNFα binding immunoglobulins.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
| Immunopharmacology Comments |
| Remtolumab neutralises the biological effects of IL-17A and TNF, which are two proinflammatory mediators of rheumatic diseases. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Phase 2 clinical candidate for RA- see NCT02433340 | |
| Psoriatic arthritis |
Disease Ontology:
DOID:9008 |
Phase 2 clinical candidate for PsA- see NCT02429895, which indicates that investigation in PsA has been terminated on business grounds. | |
